Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect
- PMID: 9719477
- DOI: 10.1016/s0006-2952(97)00615-1
Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect
Abstract
Vincristine (VCR) is an active agent in the treatment of acute lymphoblastic leukemia (ALL). We evaluated the relationship between the cytotoxic activity of VCR and the degree of VCR saturation of cellular drug binding sites, using the MOLT-3 ALL cell line. When MOLT-3 cells at a density of 1 x 10(6) or 1 x 10(8) cells/mL of pH-controlled medium were exposed to VCR for 1 hr, its cytotoxic activity on cells at high density was 10-fold less than on cells at low density (inoculum effect). The number of VCR binding sites measured by Scatchard analysis was 9.25 x 10(6)/cell. At high cell density, the saturation of VCR binding sites was one log order less than that at low density. Irrespective of cell density, curves of cell-kill versus the degree of VCR saturation of the cellular binding sites overlapped each other. Minimal cytotoxic activity was observed at 0.3% VCR saturation, and nearly maximal cytotoxic activity occurred at about 25% saturation, with the Ic50 at about 4% saturation. These data show that the VCR-induced cell-kill effect is dependent on the degree of saturation of VCR binding sites rather than on the extracellular VCR concentration. The lesser cell-kill on cells at high density can be explained by the lack of drug molecules to sufficiently saturate cellular binding sites. This phenomenon may be responsible, at least in part, for the poor chemotherapeutic outcome of ALL patients with high leukocyte counts at presentation.
Similar articles
-
Relationship between tumor cell density and drug concentration and the cytotoxic effects of doxorubicin or vincristine: mechanism of inoculum effects.Cancer Chemother Pharmacol. 1992;31(1):6-10. doi: 10.1007/BF00695987. Cancer Chemother Pharmacol. 1992. PMID: 1458560
-
Further elucidation of mechanism of resistance to vincristine in myeloid cells: role of hypochlorous acid in degradation of vincristine by myeloperoxidase.Leukemia. 2000 Jan;14(1):47-51. doi: 10.1038/sj.leu.2401627. Leukemia. 2000. PMID: 10637476
-
Vincristine induced apoptosis in acute lymphoblastic leukaemia cells: a mitochondrial controlled pathway regulated by reactive oxygen species?Int J Oncol. 2002 Dec;21(6):1339-45. doi: 10.3892/ijo.21.6.1339. Int J Oncol. 2002. PMID: 12429986
-
Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine.Cancer Chemother Pharmacol. 2013 Mar;71(3):555-64. doi: 10.1007/s00280-012-2042-4. Epub 2012 Dec 5. Cancer Chemother Pharmacol. 2013. PMID: 23212117 Free PMC article. Review.
-
Proactive therapeutic drug monitoring of vincristine in pediatric and adult cancer patients: current supporting evidence and future efforts.Arch Toxicol. 2023 Feb;97(2):377-392. doi: 10.1007/s00204-022-03418-8. Epub 2022 Nov 23. Arch Toxicol. 2023. PMID: 36418572 Review.
Cited by
-
Treatment of acute lymphoblastic leukaemia : a new era.Drugs. 2007;67(15):2153-71. doi: 10.2165/00003495-200767150-00004. Drugs. 2007. PMID: 17927282 Review.
-
Exploiting clinical trial data drastically narrows the window of possible solutions to the problem of clinical adaptation of a multiscale cancer model.PLoS One. 2011 Mar 3;6(3):e17594. doi: 10.1371/journal.pone.0017594. PLoS One. 2011. PMID: 21407827 Free PMC article.
-
Aggregation Effects and Population-Based Dynamics as a Source of Therapy Resistance in Cancer.IEEE Trans Biomed Eng. 2017 Mar;64(3):512-518. doi: 10.1109/TBME.2016.2623564. Epub 2016 Nov 1. IEEE Trans Biomed Eng. 2017. PMID: 28113286 Free PMC article.
-
Authenticity and drug resistance in a panel of acute lymphoblastic leukaemia cell lines.Br J Cancer. 2006 Dec 4;95(11):1537-44. doi: 10.1038/sj.bjc.6603447. Epub 2006 Nov 21. Br J Cancer. 2006. PMID: 17117183 Free PMC article.
-
ATP Binding Cassette C1 (ABCC1/MRP1)-mediated drug efflux contributes to disease progression in T-lineage acute lymphoblastic leukemia.Health (Irvine Calif). 2013 May;5(5A):41-50. doi: 10.4236/health.2013.55A005. Health (Irvine Calif). 2013. PMID: 24224072 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources